List of Diprivan drug patents
Diprivan is owned by Fresenius Kabi Usa.
Diprivan contains Propofol.
Diprivan has a total of 2 drug patents out of which 0 drug patents have expired.
Diprivan was authorised for market use on 02 October, 1989.
Diprivan is available in injectable;injection dosage forms.
The generics of Diprivan are possible to be released after 01 June, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8476010 | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Dec, 2024
(1 year, 10 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8476010
(Pediatric) | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Jun, 2025
(2 years from now) | |
Drugs and Companies using PROPOFOL ingredient
Market Authorisation Date: 02 October, 1989
Treatment: NA
Dosage: INJECTABLE;INJECTION
How can I launch a generic of DIPRIVAN before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic